KNSA Kiniksa Pharmaceuticals Ltd
- Stocks
- Healthcare
- NASDAQ: KNSA
Price (delayed)
$39.14
Market cap
$2.97B
P/E Ratio
79.88
Dividend/share
N/A
EPS
$0.49
Enterprise value
$2.8B
Relative Growth:
Rel. Growth:
93
Relative Strength:
Rel. Strength:
88
Relative Valuation:
Rel. Valuation:
46
Relative Profitability:
Rel. Profitability:
87
Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa's portfolio of
Highlights
KNSA's gross profit has surged by 58% year-on-year and by 15% since the previous quarter
Kiniksa Pharmaceuticals's revenue has surged by 56% YoY and by 13% QoQ
Key stats
What are the main financial stats of KNSA
Market
Valuations
Earnings
Shares outstanding
75.8M
Market cap
$2.97B
Enterprise value
$2.8B
Price to earnings (P/E)
79.88
Price to book (P/B)
5.42
Price to sales (P/S)
4.89
PEG
0.17
EV/EBIT
57.62
EV/EBITDA
52.29
EV/Sales
4.69
Revenue
$597.97M
Gross profit
$523.35M
Operating income
$38.15M
Net income
$35.92M
EBIT
$48.62M
EBITDA
$53.58M
Free cash flow
$101.73M
Per share
Balance sheet
Liquidity
EPS
$0.49
EPS diluted
$0.45
Free cash flow per share
$1.36
Book value per share
$7.22
Revenue per share
$8
TBVPS
$9.33
Total assets
$712.33M
Total liabilities
$176.95M
Debt
$9.72M
Equity
$535.38M
Working capital
$351.94M
Debt to equity
0.02
Current ratio
3.85
Quick ratio
3.27
Net debt/EBITDA
-3.08
Margins
Efficiency
Dividend
EBITDA margin
9%
Gross margin
87.5%
Net margin
6%
Operating margin
6.4%
Return on assets
5.6%
Return on equity
7.5%
Return on invested capital
14.1%
Return on capital employed
8.3%
Return on sales
8.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KNSA stock price
How has the Kiniksa Pharmaceuticals stock price performed over time
Intraday
1.56%
1 week
4.71%
1 month
1.69%
1 year
77.67%
YTD
97.88%
QTD
0.8%
Financial performance
How have Kiniksa Pharmaceuticals's revenue and profit performed over time
Revenue
$597.97M
Gross profit
$523.35M
Operating income
$38.15M
Net income
$35.92M
Gross margin
87.5%
Net margin
6%
KNSA's operating margin has surged by 194% year-on-year
KNSA's gross profit has surged by 58% year-on-year and by 15% since the previous quarter
Kiniksa Pharmaceuticals's revenue has surged by 56% YoY and by 13% QoQ
Price vs fundamentals
How does KNSA's price correlate with its fundamentals
Growth
What is Kiniksa Pharmaceuticals's growth rate over time
Valuation
What is Kiniksa Pharmaceuticals stock price valuation
P/E
79.88
P/B
5.42
P/S
4.89
EV/EBIT
57.62
EV/EBITDA
52.29
EV/Sales
4.69
KNSA's price to book (P/B) is 55% higher than its 5-year quarterly average of 3.5 and 32% higher than its last 4 quarters average of 4.1
Kiniksa Pharmaceuticals's equity has increased by 23% YoY and by 8% from the previous quarter
The stock's price to sales (P/S) is 66% less than its 5-year quarterly average of 14.2 but 29% more than its last 4 quarters average of 3.8
Kiniksa Pharmaceuticals's revenue has surged by 56% YoY and by 13% QoQ
Efficiency
How efficient is Kiniksa Pharmaceuticals business performance
The return on sales has surged by 200% since the previous quarter
Dividends
What is KNSA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KNSA.
Financial health
How did Kiniksa Pharmaceuticals financials performed over time
KNSA's total liabilities is up by 50% year-on-year and by 7% since the previous quarter
The company's total assets rose by 28% YoY and by 8% QoQ
The debt is 98% smaller than the equity
Kiniksa Pharmaceuticals's equity has increased by 23% YoY and by 8% from the previous quarter
The debt has declined by 8% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.